Eli Lilly's Foundayo Weight Loss Pill Approved by FDA, Set for April Launch
Eli Lilly Foundayo weight loss pill price, side effects, dosage, treatment: When will sales for oral weight-loss drug begin?
The Economic Times
Image: The Economic Times
Eli Lilly's weight loss pill, Foundayo (orforglipron), has received FDA approval and will launch on April 6 at a price of $149 per month. The drug is expected to generate significant sales, competing with Novo Nordisk's offerings in the GLP-1 market, despite potential side effects including gastrointestinal issues.
- 01Foundayo is a once-daily oral medication targeting the GLP-1 hormone.
- 02The pill is priced at $149 per month for self-pay customers.
- 03Analysts predict 2026 sales could reach between $1.5 billion and $2.8 billion.
- 04Common side effects include mild-to-moderate gastrointestinal issues.
- 05The drug carries a boxed warning about an increased risk of thyroid C-cell tumors.
Advertisement
In-Article Ad
Eli Lilly's weight loss pill, Foundayo (orforglipron), has secured approval from the U.S. Food and Drug Administration (FDA) and is set to launch on April 6. The medication, a once-daily oral treatment that targets the GLP-1 hormone, is priced at $149 per month for self-pay customers. In clinical trials, patients lost between 12% to 15% of their body weight. Analysts forecast that sales could reach between $1.5 billion and $2.8 billion by 2026, as it competes with Novo Nordisk's products. However, potential side effects include mild-to-moderate gastrointestinal issues, and the drug comes with a boxed warning regarding an increased risk of thyroid C-cell tumors, similar to warnings for Novo's products. Eli Lilly has also submitted Foundayo for approval in over 40 countries.
Advertisement
In-Article Ad
The launch of Foundayo may provide a new weight loss option for many Americans, potentially impacting healthcare costs and access to effective treatments.
Advertisement
In-Article Ad
Reader Poll
Are you considering using weight loss medications like Foundayo?
Connecting to poll...
More about Eli Lilly
Trump Administration Plans New Tariffs on Drugmakers Without Price Agreements
The Economic Times • Apr 2, 2026
Eli Lilly's Weight-Loss Pill Foundayo Gains FDA Approval, Competing with Novo Nordisk
The Economic Times • Apr 2, 2026
US Stock Market Rallies as Trump Hints at Possible End to Iran Conflict
The Economic Times • Apr 2, 2026
Read the original article
Visit the source for the complete story.